Detailed Study of the Ocular Hypertension-Pipeline Review, H2 2016

Ocular Hypertension-Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Ocular Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.

To view the table of contents and know more details please visit Ocular Hypertension-Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
- The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Aerie Pharmaceuticals, Inc. Allergan Plc Amakem NV Bausch & Lomb Incorporated Can-Fite BioPharma Ltd. D. Western Therapeutics Institute, Inc. F. Hoffmann-La Roche Ltd. Inotek Pharmaceuticals Corporation Ironwood Pharmaceuticals, Inc. Kowa Company, Ltd. Laboratoires Thea S.A. Laboratorios Sophia S.A. de C.V. Lee's Pharmaceutical Holdings Limited Lexicon Pharmaceuticals, Inc. NicOx S.A. Ocular Therapeutix, Inc. Otsuka Holdings Co., Ltd. pSivida Corp. Sanofi Santen Pharmaceutical Co., Ltd. Senju Pharmaceutical Co., Ltd. Sylentis S.A.U. ViSci Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###